Replies to post #669674 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

NWBO does not employ any researchers to further develop DCVAX,
The CTO lives in Europe
NWBO staff diminished from 20 to 16 people
NWBO does not have a certified CFO needed to manage the hundreds of millions that large pharma is supposed to invest for the joint trials
NWBO does NOT have any sales supporting DCVAXL after DCVAXL is approved in the UK this year.
NWBO has stopped developing Flaskworks.
DCVAXL for pediatrics has not started
No new SAP/SPA for new trials have been submitted to the FDA

NWBO is not going concern. NWBO is a shell company only holding IP and patents, therefor there is only one conclusion here that can be made which is:
After DCVAXL has been UK-approved NWBO will be bought for what I think is around 20 billion USD. I know you take the opposite of that and think DCVAXL will not be approved, you will be proven wrong it will get approved.

[biosectinvestor]

We went through this last summer, it seemed the obligations were met. Now you’re doing a rerun. This gets so f’ing tiresome with your constantly rerunning the same nonsense over and over and over again.